Search

Your search keyword '"Serrero M"' showing total 142 results
Start Over Author "Serrero M"
142 results on '"Serrero M"'

2. P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study

Author

Buisson, A, primary, Amiot, A, additional, Nachury, M, additional, Altwegg, R, additional, Serrero, M, additional, Guilmoteau, T, additional, Treton, X, additional, Caillo, L, additional, Vuitton, L, additional, Bouguen, G, additional, Pereira, B, additional, and Fumery, M, additional

Published
2024
Full Text
View/download PDF

3. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Author

Vuitton, L, primary, Poullenot, F, additional, Bouhnik, Y, additional, Wils, P, additional, Buisson, A, additional, Viennot, S, additional, Bouguen, G, additional, Hébuterne, X, additional, Gilletta, C, additional, Nancey, S, additional, Bourreille, A, additional, Amil, M, additional, Altwegg, R, additional, Goutorbe, F, additional, Caillo, L, additional, Plastaras, L, additional, Brixi, H, additional, Simon, M, additional, Serrero, M, additional, Fumery, M, additional, Rahier, J F, additional, Vicaut, E, additional, and Peyrin-Biroulet, L, additional

Published
2024
Full Text
View/download PDF

4. HIV-1 Tat protein induces production of proinflammatory cytokines by human dendritic cells and monocytes/macrophages through engagement of TLR4-MD2-CD14 complex and activation of NF-κB pathway

Author

Haij, NB, Planès, R, Leghmari, K, Serrero, M, Delobel, P, Izopet, J, BenMohamed, L, and Bahraoui, E

Abstract

Copyright © 2015 Ben Haij et al. We recently reported that the human immunodeficiency virus type-1 (HIV-1) Tat protein induced the expression of programmed death ligand-1 (PD-L1) on dendritic cells (DCs) through a TLR4 pathway. However, the underlying mechanisms by which HIV-1 Tat protein induces the abnormal hyper-activation of the immune system seen in HIV-1 infected patients remain to be fully elucidated. In the present study, we report that HIV-1 Tat protein induced the production of significant amounts of the pro-inflammatory IL-6 and IL-8 cytokines by DCs and monocytes from both healthy and HIV-1 infected patients. Such production was abrogated in the presence of anti-TLR4 blocking antibodies or soluble recombinant TLR4-MD2 as a decoy receptor, suggesting TLR4 was recruited by Tat protein. Tat-induced murine IL-6 and CXCL1/KC a functional homologue of human IL-8 was abolished in peritoneal macrophages derived from TLR4 KO but not from Wt mice, confirming the involvement of the TLR4 pathway. Furthermore, the recruitment of TLR4-MD2-CD14 complex by Tat protein was demonstrated by the activation of TLR4 downstream pathways including NF-κB and SOCS-1 and by down-modulation of cell surface TLR4 by endocytosis in dynamin and lipid-raft-dependent manners. Collectively, these findings demonstrate, for the first time, that HIV-1 Tat interacts with TLR4-MD2-CD14 complex and activates the NF-κB pathway, leading to overproduction of IL-6 and IL-8 pro-inflammatory cytokines by myeloid cells from both healthy and HIV-1 infected patients. This study reveals a novel mechanism by which HIV-1, via its early expressed Tat protein, hijacks the TLR4 pathway, hence establishing abnormal hyper-activation of the immune system.

Published
2015

5. Endoscopic Submucosal Dissection in Inflammatory Bowel Disease Patients for Visible Dysplasia: a French Retrospective Multicentric Study

Author

Anneraud, A., additional, Geyl, S., additional, Stanislas, C., additional, Schaefer, M., additional, Berger, A., additional, Serrero, M., additional, Mathieu, P., additional, Leblanc, S., additional, Wallenhorst, T., additional, Chabrun, E., additional, Chevaux, J. B., additional, Legros, R., additional, Peyrin-Biroulet, L., additional, Seksik, P., additional, Stéphane, K., additional, Dray, X., additional, Barthet, M., additional, Lepilliez, V., additional, Laharie, D., additional, Benezech, A., additional, Yzet, C., additional, Perrod, G., additional, Rahmi, G., additional, Degand, T., additional, Brieau, B., additional, Geoffroy, V., additional, Le Baleur, Y., additional, Vuitton, L., additional, and Jacques, J., additional

Published
2023
Full Text
View/download PDF

6. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

Author

Le Cosquer, G, primary, Gilletta, C, additional, Amiot, A, additional, Rivière, P, additional, Nachury, M, additional, Rouillon, C, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Fumery, M, additional, Savoye, G, additional, Biron, A, additional, Picon, L, additional, Peyrin-Biroulet, L, additional, Vidon, M, additional, Reenaers, C, additional, Simon, M, additional, Caron, B, additional, Serrero, M, additional, Altwegg, R, additional, Benezech, A, additional, Goutorbe, F, additional, Rahier, J F, additional, Beaugerie, L, additional, Pelletier, A L, additional, Caillo, L, additional, Laharie, D, additional, and Poullenot, F, additional

Published
2023
Full Text
View/download PDF

7. P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

Author

Buisson, A, primary, Serrero, M, additional, Altwegg, R, additional, Guilmoteau, T, additional, Bouguen, G, additional, Nachury, M, additional, Amiot, A, additional, Vuitton, L, additional, Treton, X, additional, Caillo, L, additional, Pereira, B, additional, and Fumery, M, additional

Published
2023
Full Text
View/download PDF

8. DOP89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study

Author

Fumery, Mathurin, Nancey, S, Nachury, M, Allez, M, Rouillon, C, Boureille, A, Altwegg, R, Serrero, M, Vuitton, L, Bouguen, G, Abitbol, V, Boualit, M, Biron, A, Panis, Y, Laharie, D, Amiot, A, Simon, M, Caillo, L, Hébuterne, X, Vidon, M, Benezech, A, Elgharabawy, Y, Peyrin-Biroulet, L, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de Chimie de Clermont-Ferrand (ICCF), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-SIGMA Clermont (SIGMA Clermont)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Technocentre Renault [Saint-Quentin-en-Yvelines], RENAULT, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Marseille, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Pontchaillou [Rennes], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier [Valenciennes, Nord], CHU Bordeaux [Bordeaux], Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Département de Gastroentérologie, and Hôpital de l'Archet 2

Subjects
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background While the effect of anti-TNFs on postoperative outcomes in patients with Crohn's disease (CD) has been widely studied, the impact of vedolizumab and ustekinumab on the risk of postoperative complications remains poorly known. Methods All consecutive patients who underwent intestinal resection for CD between July 2014 and April 2022 within 22 French centers were included in a retrospective cohort. The risk of early post-operative complications (≤30days) in patients exposed to biologics was compared to patients not exposed by logistic regression and propensity score-matched analysis adjusted for age, previous intestinal resection, corticosteroids or immunosuppressants exposure, disease activity, presence of abscess, urgent surgery and initial stoma (preoperative contra-indication to anastomosis). Results Among the 1201 patients included, respectively 491 (41%), 76 (6.3%) and 57 (4.7%) were exposed to anti-TNFs, ustekinumab, or vedolizumab within six months before surgery. A total of 317 (26.4%) patients had at least one complication of which 123 (38%) were considered as severe (DINDO III/IV). New surgery was necessary in 69 (5.7%) patients and secondary stoma in 23 (1.9%). Three deaths were observed (0.25%). The rates of overall complications in patients not exposed to biologics, exposed to anti-TNFs, ustekinumab or vedolizumab were respectively 26.1%, 25.1%, 34.7% and 29.8%. The risks of intra-abdominal infectious complications in these four groups were respectively 13.5%, 11.1%, 13.3% and 8.8%. In multivariate analysis, age [OR, 1.02 (1.01-1.04); p=0.004], disease activity [OR, 8.36 (1.79 – 149); p=0.037], the presence of an abscess [OR, 2.01 (1.25-3.20); p=0.004] and initial stoma [OR, 1.70 (1.10 –2.61); p=0.016] were significantly associated with intra-abdominal infectious complications. Conversely, preoperative enteral nutrition [OR, 0.12 (0.01 -0.59); p=0.040] was associated with a reduction in this risk. Exposure to anti-TNFs [OR, 0.80 (0.51-1.24); p=0.31], ustekinumab [OR, 1.17 (0.39-3.51); p=0.78] and vedolizumab [OR, 1.28 (0.32-5.17); p=0.72] within the 3 months before surgery were not associated with the risk of intra-abdominal infectious complications. Similar results were observed in patients exposed to these treatments in the month before surgery. Conclusion In this large cohort, a quarter of patients operated on for CD presented an early postoperative complication and 10% a severe complication. Preoperative exposure to anti-TNFs, vedolizumab or ustekinumab was not associated with an increased risk of early postoperative complications. Preoperative enteral nutrition was associated with a reduced risk of intra-abdominal infectious complication.

Published
2023

11. Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Author

Tadbiri, S., Peyrin‐Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., Buisson, A., Stefanescu, C., Trang‐Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Gilletta, C., Gagniere, C., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A.‐L., Bouguen, G., Abitbol, V., Fumery, M., Claudepierre, P., Bouhnik, Y., Amiot, A., Amiot, Aurelien, Gagniere, Charlotte, Serrero, Melanie, Grimaud, Jean‐Charles, Peyrin‐Biroulet, Laurent, Zallot, Camille, Bigard, Marc‐Andre, Filippi, Jerome, Hebuterne, Xavier, Pariente, Benjamin, Nachury, Maria, Desreumaux, Pierre, Roblin, Xavier, Del Tedesco, Emilie, Buisson, Anthony, Bommelaer, Gilles, Stefanescu, Carmen, Bouhnik, Yoram, Boureille, Arnaud, Trang‐Poisson, Caroline, Altwegg, Romain, Marteau, Philippe, Dray, Xavier, Carbonnel, Franck, Vaysse, Thibaud, Seksik, Philippe, Beaugerie, Laurent, Cosnes, Jacques, Sokol, Harry, Landman, Cecilia, Bourrier, Anne, Nancey, Stephane, Boschetti, Gilles, Laharie, David, Poullenot, Florian, Allez, Matthieu, Gornet, Jean‐Marc, Baudry, Clautilde, Savoye, Guillaume, Moreau, Jacques, Vuitton, Lucine, Koch, Stephane, Viennot, Stephanie, Aubourg, Alexandre, Picon, Laurence, Pelletier, Anne‐Laure, Sickersen, Gaelle, Bouguen, Guillaume, Abitbol, Vered, Chaussade, Stanislas, Fumery, Mathurin, Nahon, Stephane, Winkfield, Betsy, Brixi‐benmansour, Hedia, Gincul, Rodica, Barberis, Jean‐Christophe, Bonaz, Bruno, Michiels, Christophe, Zerbib, Franck, Bourrier de Beauregard, Marie, Locher, Christophe, Davin‐Couve, Sophie, Poirette, Armelle, Guillem, Laurence, Stetiu‐Mocanu, Monica, Philippe, Beau, Beorchia, Sylvain, and Al Qaddi, Jawad

Published
2018
Full Text
View/download PDF

14. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

15. Recommandations de pratique pour le diagnostic et la prise en charge de la rectocolite hémorragique

Author

Amiot, A., Viennot, S., Uzzan, M., Riviere, P., Cosquer, G.L., Yzet, C., Biron, A, Gilletta, C., Abitbol, V., Vuitton, L., Nachury, M., Simon, M., Remy, A.-J., Nahon, S., Faure, P., Guillo, L., Wils, P., Brixi, H., Bourrier, A., Serrero, M., Caillo, L., Bouguen, G., Laharie, D, Hôpital Bicêtre, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Henri Mondor, CHU Bordeaux [Bordeaux], CHU Amiens-Picardie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Mutualiste de Montsouris (IMM), Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Pré, Pierre Cherest, Hartmann], CHU Marseille, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and CHU Pontchaillou [Rennes]

Subjects
[SDV]Life Sciences [q-bio], Inflammatory Bowel Disease, diagnostic, guidelines, ulcerative colites, traitement
Abstract

National audience; Background: Updating French clinical guidelines for diagnostic and management of ulcerative colitis is needed due to the emergence of new treatments and treatment goals. Methods: On behalf of the Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID), French clinical guidelines were updated through a validated process of adaptation of clinical guidelines from international Gastroenterology societies and French consensus meetings. Results: French clinical guidelines for the diagnostic and management of ulcerative colitis were drafted by 16 GETAID members and reviewed by 6 members of the GETAID, the Association Nationale des Hépato-gastroentérologues des Hôpitaux généraux (ANGH) and the Club de Réflexion des Cabinets et Groupes d'Hépato-Gastroentérologie (CREGG), graded according to the level of Evidence and the level of agreement by 68 experts from the latter three societies. The present guidelines focused on classification, diagnosis, histopathology, extra-intestinal manifestations, dysplasia and colorectal cancer, pouchitis, medical management of active disease and maintenance therapy.. Conclusion: This paper provides updated and useful guidelines for French gastroenterologists to diagnose and treat patients with ulcerative colitis. © John Libbey Eurotext, 2022.

Published
2022

16. Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Author

Buisson, A., Nachury, M., Fumery, Mathurin, Guilmoteau, T., Leclerc, E., Altwegg, R., Serrero, M., Mathieu, N., Treton, X., Vuitton, L., Pereira, B., Amiot, A., Bouguen, G., CHU Clermont-Ferrand, Hôpital Claude Huriez [Lille], CHU Lille, CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Henri Mondor [Créteil], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and CHU Pontchaillou [Rennes]

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2022

17. DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Author

Buisson, A, primary, Nachury, M, additional, Fumery, M, additional, Guilmoteau, T, additional, Leclerc, E, additional, Altwegg, R, additional, Serrero, M, additional, Mathieu, N, additional, Treton, X, additional, Vuitton, L, additional, Pereira, B, additional, Amiot, A, additional, and Bouguen, G, additional

Published
2022
Full Text
View/download PDF

18. P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients

Author

Vuitton, L, primary, Bourrier, A, additional, Uzzan, M, additional, Nachury, M, additional, Amiot, A, additional, Roblin, X, additional, Allez, M, additional, Altwegg, R, additional, Vidon, M, additional, Bourreille, A, additional, Serrero, M, additional, Pelletier, A L, additional, Filippi, J, additional, Gilletta, C, additional, Simon, M, additional, Laharie, D, additional, Nahon, S, additional, Duveau, N, additional, Biron, A, additional, Viennot, S, additional, Abitbol, V, additional, Elgharabawy, Y, additional, and Peyrin-Biroulet, L, additional

Published
2022
Full Text
View/download PDF

19. P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

Author

Malamut, G, primary, Simon, M, additional, Nachury, M, additional, Uzzan, M, additional, Serrero, M, additional, Fumery, M, additional, Trang-Poisson, C, additional, Zallot, C, additional, Abitbol, V, additional, Charbit-Henrion, F, additional, Gornet, J M, additional, Picard, C, additional, Cerf-Bensussan, N, additional, Chaussade, S, additional, and Sokol, H, additional

Published
2022
Full Text
View/download PDF

20. DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Author

Sallette, M, primary, Bouhnik, Y, additional, Nachury, M, additional, Bellanger, C, additional, Laharie, D, additional, Amiot, A, additional, Peyrin-Biroulet, L, additional, Roblin, X, additional, Altwegg, R, additional, Buisson, A, additional, Reenaers, C, additional, Bouguen, G, additional, Vuitton, L, additional, Bourreille, A, additional, Gilletta, C, additional, Serrero, M, additional, Hébuterne, X, additional, and Filippi, J, additional

Published
2022
Full Text
View/download PDF

21. P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study

Author

Bozon, A, primary, Serrero, M, additional, Caillo, L, additional, Gilletta, C, additional, Benezech, A, additional, Nancey, S, additional, Combes, R, additional, Danan, G, additional, Akouete, S, additional, Pages, L, additional, Bourgaux, J F, additional, Boivineau, L, additional, Meszaros, M, additional, and Altwegg, R, additional

Published
2022
Full Text
View/download PDF

22. P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

Author

Lelong, M, primary, Nancey, S, additional, Bouguen, G, additional, Allez, M, additional, Serrero, M, additional, Chupin, A, additional, Caillo, L, additional, Viennot, S, additional, Blanc, P, additional, Reimund, J M, additional, Laharie, D, additional, Olivier, R, additional, Laurent, P B, additional, Dib, N, additional, De Maissin, A, additional, Montuclard, C, additional, Trang-Poisson, C, additional, Gaillot, G, additional, Bressollette-Bodin, C, additional, Berthome, M, additional, Burel, M, additional, Vavasseur, F, additional, Bourreille, A, additional, and Le Berre, C, additional

Published
2022
Full Text
View/download PDF

23. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Author

Poullenot, F, primary, Amiot, A, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bouhnik, Y, additional, Abitbol, V, additional, Nancey, S, additional, Vuitton, L, additional, Peyrin-Biroulet, L, additional, Biron, A, additional, Fumery, M, additional, Picon, L, additional, Vidon, M, additional, Reenaers, C, additional, Serrero, M, additional, Savoye, G, additional, Beaugerie, L, additional, Rivière, P, additional, and Laharie, D, additional

Published
2022
Full Text
View/download PDF

24. COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire

Author

Flachaire, B., primary, Guillo, L., additional, Avouac, J., additional, Nachury, M., additional, Carbonnel, F., additional, Bouguen, G., additional, Buisson, A., additional, Caillo, L., additional, Fumery, M., additional, Gilleta, C., additional, Hebuterne, X., additional, Lafforgue, P., additional, Laharie, D., additional, Mahé, E., additional, Marotte, H., additional, Nancey, S., additional, Ottaviani, S., additional, Salmon, J.H., additional, Guillaume, S., additional, Serrero, M., additional, Uzzan, M., additional, Viguier, M.A., additional, Richez, C., additional, Peyrin-Biroulet, L., additional, Seksik, P., additional, and Pham, T., additional

Published
2021
Full Text
View/download PDF

25. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, Mathurin, Filippi, J., Abitbol, V., Biron, A., Laharie, D., Serrero, M., Altwegg, R., Bouhnik, Y., Peyrinbiroulet, L., Gilletta, C., Roblin, X., Chambrun, G. Pineton, Vuitton, L., Bourrier, A., Nancey, S., Gornet, J. M., Nahon, S., Bouguen, G., Viennot, S., Pariente, B., Amiot, A., Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Clichy, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Pasteur [Nice] (CHU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital Claude Huriez [Lille], CHU Lille, and CHU Henri Mondor [Créteil]

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; Background: Phase III trials have demonstrated the efficacy and safety of ustekinumab in moderate-to-severe ulcerative colitis (UC), but no real-life long-term data is currently available. Methods: From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined by a partial Mayo Clinic score ≤ 2. The aim of the present study was to assess long-term effectiveness and safety of usteki numab in UC. Results: 103 UC patients (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) were included in 21 centres. History of immunomodulator, anti-TNF and vedolizumab therapies was noted in 84.5%, 99.0% and 85.4% of the cases, respectively. At week 54, 44 (43%) patients discontinued ustekinumab, for lack of efficacy (n=41), pregnancy (n=1), persistence of eczematiform lesions (n=1) or personal decision (n=1). Cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7%, and 58.4% after 3, 6, 9, and 12 months, respectively. In multivariate analysis, a CRP>5 mg/L at week 0 (OR=2.91, CI95%[1.15–7.36]; p=0.02) and concomitant steroids at week 0 (OR=3.05, CI95%[1.30–7.14]; p=0.01) were significantly associated with ustekinumab discontinuation within one year. The overall rate of steroid-free clinical remission at week 52 was 32% of whom 71% had null rectal bleeding and stool frequency Downloaded from https://academic.oup.com/ecco-jcc/article/15/Supplement_1/S486/6286779 by guest on 03 February 2022 Abstracts of the 16th Congress of ECCO - European Crohn's and Colitis Organisation S487 subscores. Ten patients (9.7%) underwent colectomy within a median of 6.7 [4.3–10.6] months. Adverse events were observed in 15 (16.9%) patients, of whom 4 (4.5%) had severe adverse events including three patients with exacerbation of UC leading to hospitalization, and a 62 years-old men who died from a myocardial infarction four months after ustekinumab initiation. Conclusion: In this real-world cohort study that included patients with refractory ulcerative colitis to multiple therapies, more than one-half of patients were still treated by ustekinumab and one-third were in steroid-free clinical remission, after 52 weeks.

Published
2021

26. P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort

Author

Uzzan, M, primary, Bresteau, C, additional, Laharie, D, additional, Stefanescu, C, additional, Carbonnel, F, additional, Serrero, M, additional, Viennot, S, additional, Nachury, M, additional, Amiot, A, additional, Altwegg, R, additional, Picon, L, additional, Nahon, S, additional, Vuitton, L, additional, Ah Soune, P, additional, Kirchgesner, J, additional, Peyrin-Biroulet, L, additional, and Bouhnik, Y, additional

Published
2021
Full Text
View/download PDF

27. P504 Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study

Author

Fumery, M, primary, Filippi, J, additional, Abitbol, V, additional, Biron, A, additional, Laharie, D, additional, Serrero, M, additional, Altwegg, R, additional, Bouhnik, Y, additional, Peyrinbiroulet, L, additional, Gilletta, C, additional, Roblin, X, additional, Pineton de Chambrun, G, additional, Vuitton, L, additional, Bourrier, A, additional, Nancey, S, additional, Gornet, J M, additional, Nahon, S, additional, Bouguen, G, additional, Viennot, S, additional, Pariente, B, additional, and Amiot, A, additional

Published
2021
Full Text
View/download PDF

28. Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

Author

Tadbiri, S., Nachury, M., Bouhnik, Y., Serrero, M., Jerome, F., Roblin, X., Bourrier, A., Bouguen, G., Franchimont, D., Savoye, G., Buisson, A., Louis, E., Nancey, S., Abtibol, V., Reimund, J. M., Dewitt, O., Vuitton, L., Matthieu, N., Peyrin-Biroulet, L., Gilletta, C., Allez, M., Viennot, S., Bourreille, A., Dib, N., Brixi, H., Boualit, M., Plastaras, L., Altwegg, R., Fumery, Mathurin, Caillo, L., Laharie, D., Amiot, A., Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pontchaillou [Rennes], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Clermont-Ferrand, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre hospitalier [Valenciennes, Nord], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

29. No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P., Seksik, P., Stefanescu, C., Nancey, S., Allez, M., Laharie, D., de Chambrun, G. Pineton, Altwegg, R., Gilletta, C., Vuitton, L., Viennot, S., Serrero, M., Fumery, Mathurin, Savoye, G., Collins, M., Goutorbe, F., Brixi, H., Bouguen, G., Tavernier, N., Boualit, M., Amiot, A., Abitbol, V., Pariente, B., Grp, Getaid, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Beaujon, Assistance Publique - Hôpitaux de Paris, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Physics, University of Surrey, University of Surrey (UNIS), Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier de la Côte Basque, CHU Pontchaillou [Rennes], Centre for Systems Biology, Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada, Programme équipe Labellisée Ligue Contre le Cancer, Institut Jacques Monod, UMR7592, Université de Paris, CNRS, Paris, France, Centre hospitalier [Valenciennes, Nord], Early detection of Colon Cancer using Molecular Markers and Microbiota (EA 7375) (EC2M3), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Claude Huriez [Lille], CHU Lille, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

31. Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

Author

Buisson, A., Fumery, Mathurin, Serrero, M., Orsat, L., Nancey, S., Riviere, P., Altwegg, R., Peyrin-Biroulet, L., Nachury, M., Hebuterne, X., Gilletta, C., Flamant, M., Viennot, S., Bouguen, G., Amiot, A., Mathieu, S., Vuitton, L., Plastaras, L., Bourreille, A., Caillo, L., Goutorbe, F., Chambrun, G. Pineton, Attar, A., Roblin, X., Pereira, B., Pariente, B., and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio]
Published
2020

32. CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease : Data from the CALM study

Author

Ungaro, R., Jordan, R., Yzet, C., Bossuyt, P., Baert, F., Vanasek, T., D'Haens, G. R., Joustra, V. Wilhelmus, Panaccione, R., Novacek, G., Reinisch, W., Armuzzi, A., Golovchenko, O., Prymak, O., Goldis, A., Travis, S., Hebuterne, X., Ferrante, M., Rogler, G., Fumery, M., Danese, S., Rydzewska, G., Pariente, B., Hertervig, E., Stanciu, C., Serrero, M., Diculescu, M., Peyrin-Biroulet, L., Laharie, D., Wright, J. P., Gomollon, F., Irina, G., Schreiber, S., Motoya, S., Hellström, P. M., Halfvarson, Jonas, Colombel, J. F., Ungaro, R., Jordan, R., Yzet, C., Bossuyt, P., Baert, F., Vanasek, T., D'Haens, G. R., Joustra, V. Wilhelmus, Panaccione, R., Novacek, G., Reinisch, W., Armuzzi, A., Golovchenko, O., Prymak, O., Goldis, A., Travis, S., Hebuterne, X., Ferrante, M., Rogler, G., Fumery, M., Danese, S., Rydzewska, G., Pariente, B., Hertervig, E., Stanciu, C., Serrero, M., Diculescu, M., Peyrin-Biroulet, L., Laharie, D., Wright, J. P., Gomollon, F., Irina, G., Schreiber, S., Motoya, S., Hellström, P. M., Halfvarson, Jonas, and Colombel, J. F.

Published
2020
Full Text
View/download PDF

34. P730 Effectiveness and safety of endoscopic balloon dilation of colorectal strictures in Crohn’s disease

Author

TILMANT, M, primary, serrero, M, additional, Poullenot, F, additional, Bouguen, G, additional, Pariente, B, additional, Altwegg, R, additional, Basile, P, additional, Filippi, J, additional, Vanelslander, P, additional, Buisson, A, additional, Vuitton, L, additional, Desjeux, A, additional, Laharie, D, additional, Le Balch, E, additional, Nachury, M, additional, Boivineau, L, additional, Savoye, G, additional, Hebuterne, X, additional, Poincloux, L, additional, Lamrani, A, additional, and Fumery, M, additional

Published
2020
Full Text
View/download PDF

35. P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study

Author

Ungaro, R, primary, Jordan, R, additional, Yzet, C, additional, Bossuyt, P, additional, Baert, F, additional, Vanasek, T, additional, D’Haens, G R, additional, Wilhelmus Joustra, V, additional, Panaccione, R, additional, Novacek, G, additional, Reinisch, W, additional, Armuzzi, A, additional, Golovchenko, O, additional, Prymak, O, additional, Goldis, A, additional, Travis, S, additional, Hébuterne, X, additional, Ferrante, M, additional, Rogler, G, additional, Fumery, M, additional, Danese, S, additional, Rydzewska, G, additional, Pariente, B, additional, Hertervig, E, additional, Stanciu, C, additional, Serrero, M, additional, Diculescu, M, additional, Peyrin-Biroulet, L, additional, Laharie, D, additional, Wright, J P, additional, Gomollón, F, additional, Irina, G, additional, Schreiber, S, additional, Motoya, S, additional, Hellström, P M, additional, Halfvarson, J, additional, and Colombel, J F, additional

Published
2020
Full Text
View/download PDF

36. P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)

Author

Buisson, A, primary, Fumery, M, additional, Serrero, M, additional, Orsat, L, additional, Nancey, S, additional, Rivière, P, additional, Altwegg, R, additional, Peyrin-Biroulet, L, additional, Nachury, M, additional, Hébuterne, X, additional, Gilletta, C, additional, Flamant, M, additional, Viennot, S, additional, Bouguen, G, additional, Amiot, A, additional, Mathieu, S, additional, Vuitton, L, additional, Plastaras, L, additional, Bourreille, A, additional, Caillo, L, additional, Goutorbe, F, additional, Pineton de Chambrun, G, additional, Attar, A, additional, Roblin, X, additional, Pereira, B, additional, and Pariente, B, additional

Published
2020
Full Text
View/download PDF

37. P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy

Author

Wils, P, primary, Seksik, P, additional, Stefanescu, C, additional, Nancey, S, additional, Allez, M, additional, Laharie, D, additional, Pineton De Chambrun, G, additional, Altwegg, R, additional, Gilletta, C, additional, Vuitton, L, additional, Viennot, S, additional, Serrero, M, additional, Fumery, M, additional, Savoye, G, additional, Collins, M, additional, Goutorbe, F, additional, Brixi, H, additional, Bouguen, G, additional, Tavernier, N, additional, Boualit, M, additional, Amiot, A, additional, Abitbol, V, additional, and Pariente, B, additional

Published
2020
Full Text
View/download PDF

38. P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease

Author

Tadbiri, S, primary, Nachury, M, additional, Bouhnik, Y, additional, Serrero, M, additional, Jerome, F, additional, Roblin, X, additional, Bourrier, A, additional, Bouguen, G, additional, Franchimont, D, additional, Savoye, G, additional, Buisson, A, additional, Louis, E, additional, Nancey, S, additional, Abtibol, V, additional, Reimund, J M, additional, DeWitt, O, additional, Vuitton, L, additional, Matthieu, N, additional, Peyrin-Biroulet, L, additional, Gilletta, C, additional, Allez, M, additional, Viennot, S, additional, Bourreille, A, additional, Dib, N, additional, Brixi, H, additional, Boualit, M, additional, Plastaras, L, additional, Altwegg, R, additional, Fumery, M, additional, Caillo, L, additional, Laharie, D, additional, and Amiot, A, additional

Published
2020
Full Text
View/download PDF

39. Efficacy of vedolizumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Nancey, S., Bouhnik, Y., Serrero, M., Armengol-Debeir, L., Buisson, Anthony, Minh, M. -L. Tran, Zallot, C., Fumery, Mathurin, Bouguen, G., Abitbol, V., Viennot, S., Chanteloup, E., Rajca, S., Dib, N., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille], Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

40. The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

Author

Amiot, A., Serrero, M., Peyrin-Biroulet, L., Filippi, J., Pariente, B., Roblin, X., Buisson, Anthony, Stefanescu, C., Trang-Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Moreau, J., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A. -L., Bouguen, G., Abitbol, V., Fumery, Mathurin, Gagniere, C., Bouhnik, Y., CHU Henri Mondor [Créteil], Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastro-entérologie et Hépatologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), STMicroelectronics [Crolles] (ST-CROLLES), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, European Crohn’s and Colitis Organisation, CHU Henri Mondor, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

41. Efficacy of ustekinumab in perianal Crohn's disease: the BioLAP multi-centre observational study

Author

Biron, C., Seksik, P., Nachury, M., Bouhnik, Y., Amiot, A., Viennot, S., Serrero, M., Fumery, Mathurin, Allez, M., Siproudhis, L., Buisson, A., Chambrun, G. Pineton, Abitbol, V., Nancey, S., Caillo, L., Plastaras, L., Armengol-Debeir, L., Chanteloup, E., Simon, M., Dib, N., Rajca, S., Amil, M., Peyrin-Biroulet, L., Vuitton, L., Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Hôpital Nord - Marseille], Hôpital Nord [CHU - APHM]-Assistance publique Hôpitaux de Marseille (APHM), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], CHU Amiens-Picardie, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital pasteur [Colmar], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de Gastro entérologie [Hôpital Paris Saint-Joseph], Hôpital Paris Saint-Joseph, Institut mutualiste Monsouris (IMM), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Louis Mourier - AP-HP [Colombes], Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and European Crohn’s and Colitis Organisation

Subjects
[SDV]Life Sciences [q-bio], [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2019

42. Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study

Author

Pineton de Chambrun, G., Pariente, B., Seksik, P., Altwegg, R., Vuitton, L., Stefasnescu, C, Nancey, S., Aubourg, A, Serrero, M, Peyrin-Biroulet, L., Filippi, J., Viennot, S, Abitbol, V., Boualit, M., Boureille, A, Moreau, J., Buisson, A., Roblin, X., Nachury, M., Zappa, M., Lambert, J., Bouhnik, Y., Study Group, Getaid-Mica, Herrada, Anthony, Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi], Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Claude Huriez [Lille], CHU Lille, Service de Gastroentérologie et nutrition [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Gastroentérologie [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépatologie et de Gastroentérologie [Lyon], Hospices Civils de Lyon (HCL), Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours], CHU Trousseau [APHP], Hôpital Nord [CHU - APHM], Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gastro-entérologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier [Valenciennes, Nord], Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Clermont-Ferrand, Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service de biostatistiques et information médicale [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de Montpellier (UM)-CHU Saint-Eloi, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-CHU Trousseau [APHP], CHU Toulouse [Toulouse], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-CHU Trousseau [APHP], and Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, medicine, Adalimumab, Abscess, Crohn's disease, business.industry, General surgery, Gastroenterology, Abdominal Abscess, Intra-abdominal Abscess, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, General Medicine, Bowel resection, medicine.disease, Crohn's Disease Activity Index, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 3. Good health, 030104 developmental biology, 030211 gastroenterology & hepatology, business, Cohort study, medicine.drug
Abstract

International audience; doi:10.1093/ecco-jcc/jjy222 Abstract P528 from the 'Poster presentations' section of the main abstract book has been withdrawn and re-inserted as DOP63 in the 'Late-breaking abstracts' section.

Published
2019

43. Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B., Peyrin-Biroulet, L., Nachury, M., Bouhnik, Y., Seksik, P., Bouguen, G., Caillo, L., Laharie, D., Carbonnel, F., Altwegg, R., Reenaers, C., Serrero, M., Boureille, A., Nancey, S., Filippi, J., Abitbol, V., Savoye, G., Vuitton, L., Viennot, S., Fumery, Mathurin, Reymond, M., Bronowicki, J. P., Reimund, J. -M., Amiot, A., Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Gastroenterology and Hepatology, University Medical Centre, Centre Hospitalier Universitaire de Nice (CHU Nice), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Registre EPIMAD, Normandie Université (NU)-Normandie Université (NU)-CHU Amiens-Picardie-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Amiens-Picardie, Périnatalité et Risques Toxiques - UMR INERIS_I 1 (PERITOX), Institut National de l'Environnement Industriel et des Risques (INERIS)-Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Département Gastroentérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Departement de Gastroentérologie, Hôpital de Hautepierre [Strasbourg], CHU Henri Mondor [Créteil], Institut des Sciences de la Terre de Paris (iSTeP), Institut national des sciences de l'Univers (INSU - CNRS)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Charles Nicolle [Rouen]-CHU Rouen, CHU Henri Mondor, and DESSAIVRE, Louise

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018

45. DOP78 Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Author

Biron, C, primary, Seksik, P, additional, Nachury, M, additional, Nancey, S, additional, Bouhnik, Y, additional, Serrero, M, additional, Armengol-Debeir, L, additional, Buisson, A, additional, Tran Minh, M-L, additional, Zallot, C, additional, Fumery, M, additional, Bouguen, G, additional, Abitbol, V, additional, Viennot, S, additional, Chanteloup, E, additional, Rajca, S, additional, Dib, N, additional, Peyrin-Biroulet, L, additional, and Vuitton, L, additional

Published
2019
Full Text
View/download PDF

46. P711 The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study

Author

Amiot, A, primary, Serrero, M, additional, Peyrin-Biroulet, L, additional, Filippi, J, additional, Pariente, B, additional, Roblin, X, additional, Buisson, A, additional, Stefanescu, C, additional, Trang-Poisson, C, additional, Altwegg, R, additional, Marteau, P, additional, Vaysse, T, additional, Bourrier, A, additional, Nancey, S, additional, Laharie, D, additional, Allez, M, additional, Savoye, G, additional, Moreau, J, additional, Vuitton, L, additional, Viennot, S, additional, Aubourg, A, additional, Pelletier, A-L, additional, Bouguen, G, additional, Abitbol, V, additional, Fumery, M, additional, Gagniere, C, additional, and Bouhnik, Y, additional

Published
2019
Full Text
View/download PDF

47. DOP74 Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study

Author

Biron, C, primary, Seksik, P, additional, Nachury, M, additional, Bouhnik, Y, additional, Amiot, A, additional, Viennot, S, additional, Serrero, M, additional, Fumery, M, additional, Allez, M, additional, Siproudhis, L, additional, Buisson, A, additional, Pineton de Chambrun, G, additional, Abitbol, V, additional, Nancey, S, additional, Caillo, L, additional, Plastaras, L, additional, Armengol-Debeir, L, additional, Chanteloup, E, additional, Simon, M, additional, Dib, N, additional, Rajca, S, additional, Amil, M, additional, Peyrin-Biroulet, L, additional, and Vuitton, L, additional

Published
2019
Full Text
View/download PDF

48. P347 Vedolizumab for primary sclerosing cholangitis associated with inflammatory bowel disease: A multicentre cohort study from the GETAID

Author

Caron, B, primary, Peyrin-Biroulet, L, additional, Nachury, M, additional, Bouhnik, Y, additional, Seksik, P, additional, Bouguen, G, additional, Caillo, L, additional, Laharie, D, additional, Carbonnel, F, additional, Altwegg, R, additional, Reenaers, C, additional, Serrero, M, additional, Boureille, A, additional, Nancey, S, additional, Filippi, J, additional, Abitbol, V, additional, Savoye, G, additional, Vuitton, L, additional, Viennot, S, additional, Fumery, M, additional, Reymond, M, additional, Bronowicki, J P, additional, Reimund, J -M, additional, and Amiot, A, additional

Published
2018
Full Text
View/download PDF

49. P458 Long-term outcome of Crohn’s disease complicated by upper gastrointestinal stricture: A GETAID cohort study

Author

Lambin, T, primary, Amiot, A, additional, Gornet, J M, additional, Seksik, P, additional, Laharie, D, additional, Louis, E, additional, Giletta, C, additional, Filippi, J, additional, Fumery, M, additional, Cadiot, G, additional, Pineton de Chambrun, G, additional, Nahon, S, additional, Serrero, M, additional, Coffin, B, additional, Plastaras, L, additional, Viennot, S, additional, Dib, N, additional, Peyrin-Biroulet, L, additional, and Pariente, B, additional

Published
2018
Full Text
View/download PDF

50. P593 Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study

Author

Briot, C, primary, Faure, P, additional, Parmentier, A L, additional, Gay, C, additional, Trang, C, additional, Nachury, M, additional, Viennot, S, additional, Altwegg, R, additional, Bulois, P, additional, Thomassin, L, additional, Serrero, M, additional, Ah Soune, P, additional, Gilletta, C, additional, Plastaras, L, additional, Simon, M, additional, Dray, X, additional, Caillo, L, additional, Del Tedeco, E, additional, Abitbol, V, additional, Zallot, C, additional, Degand, T, additional, Rossi, V, additional, Bonnaud, G, additional, Colin, D, additional, Morel, B, additional, Danset, J B, additional, Winkfield, B, additional, Filippi, J, additional, Amiot, A, additional, Attar, A, additional, Bourreille, A, additional, Grimaud, J C, additional, Blain, A, additional, Peyrin Biroulet, L, additional, and Vuitton, L, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results